Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer
Authors
Simões, Bruno M.; orcid: 0000-0003-1253-6657; email: bruno.simoes@manchester.ac.ukSantiago-Gómez, Angélica
Chiodo, Chiara
Moreira, Tiago
Conole, Daniel; orcid: 0000-0002-3389-8377
Lovell, Scott
Alferez, Denis
Eyre, Rachel
Spence, Katherine
Sarmiento-Castro, Aida
Kohler, Bertram
Morisset, Ludivine
Lanzino, Marilena
Andò, Sebastiano
Marangoni, Elisabetta
Sims, Andrew H.; orcid: 0000-0001-9082-3665
Tate, Edward W.; orcid: 0000-0003-2213-5814
Howell, Sacha J.; orcid: 0000-0001-8141-6515; email: sacha.howell@christie.nhs.uk
Clarke, Robert B.; orcid: 0000-0001-5407-3123; email: robert.clarke@manchester.ac.uk
Publication Date
2020-05-30Submitted date
2020-02-21
Metadata
Show full item recordAbstract
Abstract: Estrogen receptor (ER) positive breast cancer is frequently sensitive to endocrine therapy. Multiple mechanisms of endocrine therapy resistance have been identified, including cancer stem-like cell (CSC) activity. Here we investigate SFX-01, a stabilised formulation of sulforaphane (SFN), for its effects on breast CSC activity in ER+ preclinical models. SFX‐01 reduced mammosphere formation efficiency (MFE) of ER+ primary and metastatic patient samples. Both tamoxifen and fulvestrant increased MFE and aldehyde dehydrogenase (ALDH) activity of patient-derived xenograft (PDX) tumors, which was reversed by combination with SFX‐01. SFX-01 significantly reduced tumor-initiating cell frequency in secondary transplants and reduced the formation of spontaneous lung micrometastases by PDX tumors in mice. Mechanistically, we establish that both tamoxifen and fulvestrant induce STAT3 phosphorylation. SFX-01 suppressed phospho‐STAT3 and SFN directly bound STAT3 in patient and PDX samples. Analysis of ALDH+ cells from endocrine-resistant patient samples revealed activation of STAT3 target genes MUC1 and OSMR, which were inhibited by SFX-01 in patient samples. Increased expression of these genes after 3 months’ endocrine treatment of ER+ patients (n = 68) predicted poor prognosis. Our data establish the importance of STAT3 signaling in CSC-mediated resistance to endocrine therapy and the potential of SFX-01 for improving clinical outcomes in ER+ breast cancer.Citation
Oncogene, volume 39, issue 25, page 4896-4908Publisher
Nature Publishing Group UKType
articleDescription
From Springer Nature via Jisc Publications RouterHistory: received 2020-02-21, rev-recd 2020-05-13, accepted 2020-05-15, registration 2020-05-16, pub-electronic 2020-05-30, online 2020-05-30, pub-print 2020-06-18
Publication status: Published
Funder: DH | National Institute for Health Research (NIHR); doi: https://doi.org/10.13039/501100000272; Grant(s): IS-BRC-1215-20007, IS-BRC-1215-20007, IS-BRC-1215-20007
Funder: Breast Cancer Now; doi: https://doi.org/10.13039/501100007913; Grant(s): MAN-Q2
Funder: National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs); doi: https://doi.org/10.13039/501100000849; Grant(s): NC/T001267/1
Funder: RCUK | Medical Research Council (MRC); doi: https://doi.org/10.13039/501100000265; Grant(s): MR/K501311/1